Val Hansen, MD
Internal Medicine · Bountiful, UTNPI 1235224296
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,826 of the $5,051 with a category attached, or 75.7%. 44 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 29.7% of the total. Reporting peaked in 2020 at $1,995 and has fallen 99.1% since, to $17 in 2025.
Across 238 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Astellas Pharma US Inc$311
- Pfizer$276
- Novartis$259
- Amgen$226
- Amarin Pharma, Inc.$216
- plus $2K from 38 others
Across 52 payments — averaging $2812.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$59K
- Shire North American Group Inc$30K
- Takeda Pharmaceuticals U.S.A., Inc.$27K
- AbbVie$27K
- Janssen Research & Development, LLC$2K
- Eli Lilly$2K
What the payments were for
- Travel & lodging$1,22524%
- Food & beverage$3,82676%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,051 in reported general payments places this provider in the 85th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $21,720 |
| XareltoRivaroxaban | 20 | $19,153 |
| EliquisApixaban | 19 | $17,063 |
| FarxigaDapagliflozin Propanediol | 15 | $13,907 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,799 |
| JanuviaSitagliptin Phosphate | 13 | $7,182 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,932 |
| Novolog FlexpenInsulin Aspart | 14 | $2,801 |
| HumalogInsulin Lispro | 14 | $2,241 |
| Insulin Lispro | 12 | $1,997 |
| Omeprazole | 102 | $1,975 |
| Levothyroxine Sodium | 196 | $1,973 |
| Estradiol | 24 | $1,764 |
| Potassium Chloride | 69 | $1,529 |
| Irbesartan | 87 | $1,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $67 | $21,72017 claims |
| Johnson & JohnsonXarelto | $184 | $19,15320 claims |
| PfizerEliquis | $276 | $17,06319 claims |
| AstraZenecaFarxiga | $184 | $13,90715 claims |
| MerckJanuvia | $74 | $7,18213 claims |
| Lilly USA, LLCHumalog, Insulin Lispro | $189 | $4,23826 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $1,973196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Bountiful
- Joshua OaksBountiful$16K
- Lisani EstopinanBountiful$6K
- Scott SouthworthBountiful$6K
- Willard DereSalt Lake City$4.7M
- Kenneth SchaecherWest Valley City$333K
- Steven CallSpringville$178K
- James ChamberlainSalt Lake City$106K
- Alexander PastuszakSalt Lake City$87K
- Zameer AbedinSalt Lake City$83K
- Kashif MemonVernal$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.